Drug Profile

Dapagliflozin/Rosuvastatin - CMG Pharmaceutical

Alternative Names: CMG-190303

Latest Information Update: 24 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CMG Pharmaceutical
Class Anti-ischaemics; Antihyperglycaemics; Antihyperlipidaemics; Antivirals; Benzhydryl compounds; Cardiovascular therapies; Chlorobenzenes; Fluorobenzenes; Glucosides; Heart failure therapies; Hepatoprotectants; Obesity therapies; Pyrans; Pyrimidines; Small molecules; Sulfonamides; Urologics
Mechanism of Action HMG-CoA reductase inhibitors; Sodium-glucose transporter 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

19 Apr 2024 Phase-III clinical trials in Dyslipidaemias (Treatment-experienced) in South Korea (unspecified route) (NCT06772168)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com